Update on Mechanical Circulatory Support. AATS May 5, 2010 Toronto, ON Canada
|
|
- Alban Lee
- 5 years ago
- Views:
Transcription
1 Update on Mechanical Circulatory Support AATS May 5, 2010 Toronto, ON Canada
2 Disclosures NONE
3 Emergency Circulatory Support ECMO Tandem Heart Impella
4 Assessment Cardiac Function Pulmonary function Valvular function Recovery likely?
5 ECMO Flow rate : 0 5 L/min Percutaneous or open Versatile : R / L Support Allows for easier patient transportation
6
7
8
9 SURVIVAL % Cardiac failure Respiratory failure 24% Years
10 RISK FACTORS Advancing age Subsystem dysfunction Thoracic aorta operation Reoperation
11 LIKELIHOOD OF WITHDRAWAL Pre-ECMO factors Advancing age Subsystem dysfunction No IABP + On-ECMO factors Complications on ECMO
12 Cumulative Survival Freedom from death of any cause after extracorporeal membrane oxygenation implantation for postcardiotomy cardiogenic shock Follow-up (y) Rastan et al: JTCS: Feb 2010
13 ECMO for PCCS: % 6 month and 1 year survival Risk factors: Age>70, complex operations, diabetes and pre-op CRI Dialysis-65% Reop-60% Stroke- 17% Blood in 48hrs-30 units +/- 26 Rastan etal JTCVS Feb 2010: Heart Center University of Leipzig
14 IMPELLA
15 Impella Technology Peripheral Insertion Platforms Impella 5.0 Impella 2.5 HCS-P M1
16 Impella 2.5 or 5.0 Miniaturized Blood Pump Technology 21 Fr micro-axial pump 9 Fr catheter-based platform Delivers up to L/min blood flow support Minimally Invasive Peripheral Placement 9 Fr catheter-based platform Single peripheral insertion point Femoral Artery Cut-down HCS-P M1
17 Use of Impella Recover 2.5 LVAD in patients with cardiogenic shock or undergoing high risk PCI: Experience of a High Volume Center Vecchio et al Minerva Cardioloangiol patients 6 cardiogenic shock 5 high risk PCI 7 patients had bleeding (5 with shock) Only 2 patients had significant hemodynamic improvement All PCI patients were discharged Only 2 patients in shock were discharged Conclusion : Impella is feasible and safe but may be insufficient in reversing advance cardiogenic shock which, probably, has to be treated with more powerful LVADs
18 Impella Merits Miniturized Percutaneous Support Uni-ventricular Max support : days LV unloading Bleeding Limitations Limb ischemia Infection with longer support times Need for fluoroscopic support for positioning LD : cumbersome technology
19 TandemHeart
20 Left Sided Support
21 Feasibility study of a temporary percutaneous LVAD in cardiac surgery Pitsis et al Ann Thorac Surgery male patients Post cardiotomy unable to wean from CPB Mean duration of support : 88 hrs Weaning rate : 72% Survival to discharge : 54.5 % 1 year survival : 45% 4 year survival : 36.3 % Main complication was bleeding
22 TandemHeart Merits Miniaturized Percutaneous Support Uni-ventricular Bi-ventricular Max support : 3 weeks LV unloading?? Bleeding Hemolysis Limitations Limb ischemia Infection with longer support times Need of X-ray capability for implantation
23 Narrowing the Field s 1990 s and 2000 s
24 Narrowing the Field-2010 Heartware HM II BTT:DT Debakey/HeartAssist 5 Duraheart BTT;submitted DT Levacor:BTT Jarvik
25 HeartMate II vs HeartMate XVE LVAD Continuous-flow LVAD (HM II) 1/7 size; 1/4 weight Quiet 40% smaller lead One moving part long term durability Pulsatile-flow LVAD (HM XVE) Large size Noisy Large percutaneous lead Limited durability
26 DT and BTT (Including BTT CAP) Percent Survival 100 BTT (first 133 HM II patients) Miller, Pagani, Russell et al NEJM Pagani, Miller, Russell et al JACC Slaughter, Rogers, Milano et al NEJM 2009 BTT (first =281 HM II patients) 2 73% 68% Months 58% DT (first 133 HM II Patients) 3
27 Heartware Kaplan-Meier Survival Curve Clinical Trial Patients (n =50) Commercial Patients (n = 50) 90% 85% 77% 90% 87% 180 days 180 days Data as of Feb 2010 Strueber, et al. ISHLT Annual Meeting 2010
28 % Survival 100 Primary LVADs (n=1,092) intermacs: June 2006 March Continuous flow pump n=548, deaths=51 Pulsatile pump n=406, deaths=95 20 p< Months after Device Implant Kirklin et al: JHLT, January 2010
29 Survival on MCS Continuous Flow % Pulsatile 20 p= Months
30 Actuarial Survival vs REMATCH* HeartMate II Destination Therapy Trial Percent Survival % CF LVAD 58% 55% 52% LVAD REMATCH: 23% 25% PF LVAD 24% OMM REMATCH 8% Months * N Engl J Med 2001; 345:
31 % Survival Device Strategy at Implant intermacs: June 2006 March BTT=496, deaths=54 BTC=458, deaths=92 60 DT=100, deaths= Primary LVAD n=1,092 p< Months after Device Implant Kirklin et al: JHLT, January 2010
32 Proportion of Patients Destination Therapy Competing Outcomes intermacs: June 2006 March Alive 55% device in place Primary LVAD DT: n= Death 35% before Tx Transplant 10% Explant 0% recovery Months after Device Implant Kirklin et al: JHLT, January 2010
33 RV Dysfunction: Often ignored
34 BTT 90% of patients can get by with just an LVAD DT 10-15% of patients continue with RV dysfunction Slide furnished by Thoratec, Inc
35 Survival to Transplantation 100 p= p=0.054 p=0.106 % LVAD P-BiVAD D-BiVAD Fitzpatrick et al, JTCS: April 2009
36 Survival to Hospital Discharge 100 P< p=0.002 p=0.046 % LVAD P-BiVAD D-BiVAD Fitzpatrick et al, JTCS: April 2009
37 Survival Distribution Function % LVAD P-BiVAD D-BiVAD Survival Time (days) Fitzpatrick et al, JTCS: April 2009
38 Predictors of RV dysfunction RVSWI < 600 mm Hg xml/m2 CVP >15 or >PCWP Pre-operative vent support T bili >2.0 Creatinine >2.5 Fevers within 24 hrs
39 2 21 French Transseptal Catheters
40 % Survival Survival by Device Type intermacs: June 2006 March 2009 (n=1,420) TAH n=51, deaths=10 Bi-VAD n=193, deaths=66 LVAD n=1158, deaths= RVAD n=18, deaths=3 p (overall) < Months after Device Implant Kirklin et al: JHLT, January 2010
41 OUTCOMES: PATIENT RISK PROFILE PERSPECTIVE
42 % Survival p =.002 Event: Death (censored at transplant) Levels 2-7: All Others, n=234, deaths=49 Level 1 (Critical Cardiogenic Shock), n=186, deaths= Months after Device Implant Implant Dates: Jun 23, 2006 Dec 31, 2007 Patient Survival Among Profiles
43 Sequence of Devices ECMO LVAD RVAD BIVAD TAH 1 st nd rd th
44 Sequence of MCS Support 1 st 2 nd 3 rd 4 th EHMO LVAD 54 RVAD 1 ECMO RVAD 1 12 LVAD 1 RVAD ECMO BiVAD 12 ECMO RVAD 1 LVAD 17 LVAD 2 2 ECMO LVAD 286 RVAD 13 BiVAD 1 TAH 1 ECMO 1 ECMO LVAD 14 BiVAD 1 3 BiVAD LVAD RVAD BiVAD 2 RVAD TAH 5 TAH
45 100 Survival on MCS Device Number % Months
46 Risk Factors for Death on MCS Early phase More devices Cachexia Pre MCS higher BUN Devices other than LVAD
47 Risk Factors for Death on MCS Constant Hazard More Devices Pre MCS HTN Pre MCS Dialysis Pre MCS ventilatory support Neuro events on MCS
48 Risk Factors for Death after Implant in 1,092 Primary LVADs (INTERMACS: June 2006-March 2009) Early Constant Risk factor HR p-value HR p-value Age (older) 2.42 < Bilirubin (higher) RA pressure (higher) Cardiogenic shock BTC or DT Pulsatile pump Kirklin et al: JHLT, January 2010
49 # of Patients Survival (%) Columbia High Risk (n=3) Low Risk (n=83) High Risk (score >5) (n=3) Risk Score Months Schaffer et al, Ann Thorac Surg: 2009
50 # of Patients Survival (%) Leitz-Miller High Risk (n=33) 6 4 High Risk (score >17) (n=33) Low Risk (n=53) Risk Score Months Schaffer et al, Ann Thorac Surg: 2009
51 # of Patients Survival (%) INTERMACS Low Risk (n=43) 20 High Risk (score >2) (n=43) High Risk (n=43) Risk Score Months Schaffer et al, Ann Thorac Surg: 2009
52 # of Patients Survival (%) SHFM-HM II 15 High Risk (score >3.533) (n=31) Low Risk (n=55) High Risk (n=31) Risk Score Months Schaffer et al, Ann Thorac Surg: 2009
53 300 Preoperative MELD Score vs TBPE TBPE (units) MELD Matthews et al, Circulation: Jan 2010
54 MCS Fewer devices Select one or two that works for you Increased selectivity of cases Increase value added for expensive technology-reduced morbidity.
55 Feasibility study of the use of Tandem Heart percutaneous VAD for Treatment of cardiogenic shock Burhoff et al Cath Cardiovasc Interv patients with cardiogenic shock 6 month follow-up Support duration: 60 +/- 44 hrs 10 (77%) patients survived to device explant 6 (60%) of these bridged to another therapy 7 (53 %) patients survived to hospital discharge 7 (53%) alive at 6 months Two most common complications 3 (23%) distal limb ischemia 4 (30%) bleeding from cannulation site
56 Use of the Percutaneous LVAD in Patients with Severe Refractory Cardiogenic Shock as a Bridge to Long-term LVAD Implantation Idelchick et al J Heart Lung Transpl patients All in persistent cardiogenic shock to IABP and inotropes All were as a bridge to LVAD or heart transplantation Mean duration of support : 4.2 days (+/- 2.5 days) 4 patients terminated support before LVAD 14 successfully bridged to LVAD or Heart Transplantation Complications: Right common femoral artery dissection Blood transfusions in 8 patients Infection with positive b/c in 8 patients 30 day mortality : 27% 6 month mortality : 33%
57 The TandemHeart as a Bridge to a Long-Term Axial-Flow LVAD Gregoric et al Texas Heart Inst end-stage heart failure patients All in acute hemodynamic decompensation Mean age 37 yrs Tandem as a bridge to axial flow pump Days of Tandem : 5.9 days (range 1-22 days) 3 BTT 5 continued on axial flow pump, 1 ( 11%) died after converted to an axial flow pump
58 Clinical Experience with the TandemHeart Percutaneous VAD as a Bridge to Cardiac Transplantation Bruckner et al Tex Heart Inst J heart failure patients 2 NICM 3 ICM Mean duration of support : 7.6 days (+/- 3.2 days) All successfully BTT
59 Usefulness of percutaneous LVAD as a bridge to recovery from myocarditis Chandra et al Am J Cardiol patients with acute myocarditis All in severe cardiogenic shock All successfully bridged to recovery with Tandem Mean duration of support : 5 days (range 2 8 days) All survived to discharge
60 Randomized comparison of intra-aortic balloon support with a percutaneous LVAD in patients with revascularized AMI complicated by cardiogenic shock Thiele et al Eur Heart J 2005 Randomized trial of IABP vs perc VAD Patients in cardiogenic shock following AMI Going for PCI of the occluded vessel IABP, n = 20 and pvad, n = 21 p VAD better in improving cardiac index, hemodynamic and metabolic variables pvad had more severe bleeding (n=19 vs. 8, p=0.002) and more limb ischemia (n = 7 vs. n = 0, p=0.009) 30-day mortality was similar (IABP 45% vs pvad 43%, p = 0.86)
61 Left Ventricular Mechanical Support with the Impella Recover Left Direct Microaxial Blood Pump: A Single Center Experience Garati et al Artif Organs patients 6 supported as BTT 3 treated for fulminant acute myocarditis 3 Post cardiotomy low-output Mean support time : 8.8 days (+/- 2.3 days) Overall mortality : 50% 4 patients were successfully BTT; the 2 other died on the device 2 patients with myocarditis died of septic shock 2 patients with post-cardiotomy syndrome died of MSOF 2 patients were weaned
62 Initial experiences with the Impella device in patients with cardiogenic shock Impella support for cardiogenic shock Meyns et al Thorac Cardiovasc Surg patients in cardiogenic shock 10 post cardiotomy heart failure All placed directly through the aorta 6 in coronary unit Through the femoral 3 patients the device was used in combination with ECMO Device related complications: 3 sensor failures 1 pump displacement 6 incidences of hemolysis 11 patients weaned 6 patients survived
63 A randomized clinical trial to evaluate the safety and efficacy of a percutaneous LVAD versus IABP for treatment of cardiogenic shock caused by MI Seyfarth et al J Am Coll Cardiol 2008 Prospective randomized trial All with cardiogenic shock 25 patients 13 IABP 12 Impella LP 2.5 Impella better at providing hemodynamical support than IABP 30 day mortality for both groups = 46%
DECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST Cardiogenic Shock Mechanical Support Eulàlia Roig FESC Heart Failure and HT Unit Hospital Sant Pau - UAB Barcelona. Spain No conflics of interest Mechanical Circulatory
More informationMechanical Cardiac Support in Acute Heart Failure. Michael Felker, MD, MHS Associate Professor of Medicine Director of Heart Failure Research
Mechanical Cardiac Support in Acute Heart Failure Michael Felker, MD, MHS Associate Professor of Medicine Director of Heart Failure Research Disclosures Research Support and/or Consulting NHLBI Amgen Cytokinetics
More informationเอกราช อร ยะช ยพาณ ชย
30 July 2016 เอกราช อร ยะช ยพาณ ชย Heart Failure and Transplant Cardiology aekarach.a@chula.ac.th Disclosure Speaker, CME service: Merck, Otsuka, Servier Consultant, non-cme service: Novartis, Menarini
More informationManagement of Acute Shock and Right Ventricular Failure
Management of Acute Shock and Right Ventricular Failure Nader Moazami, MD Department of Thoracic and Cardiovascular Surgery and Biomedical Engineering, Cleveland Clinic NONE Disclosures CARDIOGENIC SHOCK
More informationAndrew Civitello MD, FACC
Timing the Transition from Short Term to Long Term Mechanical Circulatory Support Andrew Civitello MD, FACC Medical Director, Heart Transplant Program Director, Fellowship Co-Director, Baylor St. Luke's
More informationVentricular Assist Devices for Permanent Therapy: Current Status and Future
Ventricular Assist Devices for Permanent Therapy: Current Status and Future Prospects Francis D. Pagani MD PhD Professor of Cardiac Surgery University of Michigan April 28 th, 2012 Disclosures NHLBI and
More informationAllinaHealthSystem 1
: Definition End-organ hypoperfusion secondary to cardiac failure Venoarterial ECMO: Patient Selection Michael A. Samara, MD FACC Advanced Heart Failure, Cardiac Transplant & Mechanical Circulatory Support
More informationCirculatory Support: From IABP to LVAD
Circulatory Support: From IABP to LVAD Howard A Cohen, MD, FACC, FSCAI Director Division of Cardiovascular Intervention Co Director Cardiovascular Interventional ti Laboratories Lenox Hill Heart & Vascular
More informationMechanical assist patient selection, device selection, and outcomes
Mechanical assist patient selection, device selection, and outcomes Josef Stehlik, MD, MPH Associate Professor of Medicine Medical Director, Heart Transplant Program University of Utah School of Medicine
More informationExtra Corporeal Life Support for Acute Heart failure
Extra Corporeal Life Support for Acute Heart failure Benjamin Medalion, MD Director Heart and Lung Transplantation Department of Cardiothoracic Surgery Rabin Medical Center, Beilinson Campus, Israel Mechanical
More informationRight Ventricular Failure: Prediction, Prevention and Treatment
Right Ventricular Failure: Prediction, Prevention and Treatment 3 rd European Training Symposium for Heart Failure Cardiologists and Cardiac Surgeons University Hospital Bern June 24-25, 2016 Disclosures:
More informationCase - Advanced HF and Shock (INTERMACS 1)
Case - Advanced HF and Shock (INTERMACS 1) Navin K. Kapur, MD, FACC, FSCAI, FAHA Associate Professor, Department of Medicine Interventional Cardiology & Advanced Heart Failure Programs Executive Director,
More informationMechanical Circulatory Support for Unstable Heart Failure
Mechanical Circulatory Support for Unstable Heart Failure Michael A. Acker, MD William Measey Professor of Surgery Chief of Cardiovascular Surgery University of Pennsylvania Health System O.H. Frazier,
More informationIntroduction to Acute Mechanical Circulatory Support
Introduction to Acute Mechanical Circulatory Support Navin K. Kapur, MD, FACC, FSCAI, FAHA Associate Professor, Department of Medicine Interventional Cardiology & Advanced Heart Failure Programs Executive
More informationLow cardiac output & Mechanical Support นายแพทย อรรถภ ม ส ศ ภอรรถ ศ ลยศาสตร ห วใจและทรวงอก โรงพยาบาล ราชว ถ
Low cardiac output & Mechanical Support นายแพทย อรรถภ ม ส ศ ภอรรถ ศ ลยศาสตร ห วใจและทรวงอก โรงพยาบาล ราชว ถ Low cardiac output/cardiogenic Shock State of end-organ hypoperfusion due to cardiac failure.
More informationConcomitant Aortic Valve Procedures in Patients Undergoing Implantation of Continuous-Flow LVADs: An INTERMACS Database Analysis
Concomitant Aortic Valve Procedures in Patients Undergoing Implantation of Continuous-Flow LVADs: An INTERMACS Database Analysis April 11, 2014 Jason O. Robertson, M.D., M.S.; David C. Naftel, Ph.D., Sunil
More informationManagement of Cardiogenic Shock. Dr Stephen Pettit, Consultant Cardiologist
Dr Stephen Pettit, Consultant Cardiologist Cardiogenic shock Management of Cardiogenic Shock Outline Definition, INTERMACS classification Medical management of cardiogenic shock PA catheters and haemodynamic
More informationPediatric Mechanical Circulatory Support - What to Use
Pediatric Mechanical Circulatory Support - What to Use Ronald K. Woods, MD, PhD Associate Professor Medical College of Wisconsin Pediatric Cardiothoracic Surgery Children s Hospital of Wisconsin Disclosure
More informationSurgical Options for Temporary MCS
Surgical Options for Temporary MCS Michael A. Acker, MD Julian Johnson Professor of Surgery Chief of Cardiovascular Surgery Director of Heart and Vascular Center University of Pennsylvania Health System
More informationPredicting Major Outcomes after MCSD Implant. Risk Factors for Death, Transplant, and Recovery. James Kirklin, MD David Naftel, PhD
Predicting Major Outcomes after MCSD Implant Risk Factors for Death, Transplant, and Recovery James Kirklin, MD David Naftel, PhD 1 I have no financial disclosures (I am the Principle Investigator for
More informationECMO as a bridge to durable LVAD therapy. Jonathan Haft, MD Department of Cardiac Surgery University of Michigan
ECMO as a bridge to durable LVAD therapy Jonathan Haft, MD Department of Cardiac Surgery University of Michigan Systolic Heart Failure Prevalence 4.8 million U.S. 287,000 deaths per year $39 billion spent
More informationRamani GV et al. Mayo Clin Proc 2010;85:180-95
THERAPIES FOR ADVANCED HEART FAILURE: WHEN TO REFER Navin Rajagopalan, MD Assistant Professor of Medicine University of Kentucky Director, Congestive Heart Failure Medical Director of Cardiac Transplantation
More informationCounterpulsation. John N. Nanas, MD, PhD. Professor and Head, 3 rd Cardiology Dept, University of Athens, Athens, Greece
John N. Nanas, MD, PhD Professor and Head, 3 rd Cardiology Dept, University of Athens, Athens, Greece History of counterpulsation 1952 Augmentation of CBF Adrian and Arthur Kantrowitz, Surgery 1952;14:678-87
More informationLVADs as a long term or destination therapy for the advanced heart failure
LVADs as a long term or destination therapy for the advanced heart failure Prof. Davor Miličić, MD, PhD University of Zagreb School of Medicine Department of Cardiovascular Diseases University Hospital
More informationCath Lab Essentials : LV Assist Devices for Hemodynamic Support (IABP, Impella, Tandem Heart, ECMO)
Cath Lab Essentials : LV Assist Devices for Hemodynamic Support (IABP, Impella, Tandem Heart, ECMO) Michael A. Gibson, MD Assistant Professor of Medicine University of California, Irvine Division of Cardiology
More informationMechanics of Cath Lab Support Devices
Mechanics of Cath Lab Support Devices Issam D. Moussa, MD Chief Medical Officer First Coast Cardiovascular Institute, Jacksonville, FL Professor of Medicine, UCF, Orlando, FL None DISCLOSURE Percutaneous
More informationMechanical Circulatory Support in the Management of Heart Failure
Mechanical Circulatory Support in the Management of Heart Failure Feras Bader, MD, MS, FACC Associate Professor of Medicine Director, Heart Failure and Transplant Cleveland Clinic Abu Dhabi Chairman, Heart
More informationBridging With Percutaneous Devices: Tandem Heart and Impella
Bridging With Percutaneous Devices: Tandem Heart and Impella DAVID A. BARAN, MD, FACC, FSCAI SYSTEM DIRECTOR, ADVANCED HEART FAILURE, TX AND MCS SENTARA HEART HOSPITAL NORFOLK, VA PROFESSOR OF MEDICINE
More informationEcho assessment of patients with an ECMO device
Echo assessment of patients with an ECMO device Evangelos Leontiadis Cardiologist 1st Cardiology Dept. Onassis Cardiac Surgery Center Athens, Greece Gibbon HLM 1953 Goldstein DJ et al, NEJM 1998; 339:1522
More informationSurgical Options for Advanced Heart Failure
Surgical Options for Advanced Heart Failure Benjamin Medalion, MD Director, Transplantation and Heart Failure Surgery Department of Cardiothoracic Surgery Rabin Medical Center, Beilinson Hospital Heart
More informationLeft Ventricular Assist Devices (LVADs): Overview and Future Directions
Left Ventricular Assist Devices (LVADs): Overview and Future Directions FATIMA KARAKI, M.D. PGY-3, DEPARTMENT OF MEDICINE WASHINGTON UNIVERSITY IN ST. LOUIS ST. LOUIS, MISSOURI, USA St. Louis, Missouri,
More informationA Validated Practical Risk Score to Predict the Need for RVAD after Continuous-flow LVAD
A Validated Practical Risk Score to Predict the Need for RVAD after Continuous-flow LVAD SK Singh MD MSc, DK Pujara MBBS, J Anand MD, WE Cohn MD, OH Frazier MD, HR Mallidi MD Division of Transplant & Assist
More informationRight Heart Failure in LVAD patients: Prevention and Management.
Christian Bermudez MD. Associate Professor Director Thoracic Transplantation Division Cardiac Surgery Department of Surgery University of Pennsylvania Right Heart Failure in LVAD patients: Prevention and
More informationNovel Devices for End-Stage Heart Failure
Novel Devices for End-Stage Heart Failure Lynne Warner Stevenson No conflicts of interest Off-label assist devices and expanded indications will be discussed Devices for End-Stage Heart Failure New definitions
More informationBridge to Heart Transplantation
Bridge to Heart Transplantation Ulf Kjellman MD, PhD Senior Consultant Surgeon Heart Centre KFSH&RC 1 Disclosure Appointed for Proctorship by Thoratec/St.Jude/Abbott 2 To run a full overall covering transplant
More informationMechanics of Cath Lab Support Devices
Mechanics of Cath Lab Support Devices Issam D. Moussa, MD Professor of Medicine Mayo Clinic College of Medicine Chair, Division of Cardiovascular Diseases Mayo Clinic Jacksonville, Florida DISCLOSURE Presenter:
More informationMechanical circulatory support in cardiogenic shock The Cardiologist s view ACCA Masterclass 2017
Mechanical circulatory support in cardiogenic shock The Cardiologist s view ACCA Masterclass 2017 Pascal Vranckx MD, PhD. Medical director Cardiac Critical Care Services Hartcentrum Hasselt Belgium Disclosure
More informationThe Role of Mechanical Circulatory Support in Cardiogenic Shock: When to Utilize
The Role of Mechanical Circulatory Support in Cardiogenic Shock: Presented by Nancy Scroggins ACNP, CNS-CC CV Surgery ACNP Bayshore Medical Center The Role of Mechanical Circulatory Support in Cardiogenic
More informationTed Feldman, M.D., MSCAI FACC FESC
Support Technologies and High Risk Intervention Patient Selection: When Not to Use Them Ted Feldman, M.D., MSCAI FACC FESC Evanston Hospital SCAI Fall Fellows Course Las Vegas December 7-10 th, 2014 Ted
More informationUnderstanding the Pediatric Ventricular Assist Device
Understanding the Pediatric Ventricular Assist Device W. James Parks, MSc., MD Pediatric Cardiologist Assistant Professor of Pediatrics and Radiology Children s Healthcare of Atlanta Sibley Heart Center
More informationAcute Mechanical Circulatory Support Right Ventricular Support Devices
Acute Mechanical Circulatory Support Right Ventricular Support Devices Navin K. Kapur, MD, FACC, FSCAI, FAHA Associate Professor, Department of Medicine Interventional Cardiology & Advanced Heart Failure
More informationFifth INTERMACS annual report: Risk factor analysis from more than 6,000 mechanical circulatory support patients
http://www.jhltonline.org SPECIAL FEATURE Fifth INTERMACS annual report: Risk factor analysis from more than 6, mechanical circulatory support patients James K. Kirklin, MD, a David C. Naftel, PhD, a Robert
More informationAssist Devices in STEMI- Intra-aortic Balloon Pump
Assist Devices in STEMI- Intra-aortic Balloon Pump Ioannis Iakovou, MD, PhD Onassis Cardiac Surgery Center Athens, Greece Cardiogenic shock 5-10% of pts after a heart attack 60000-70000 pts in Europe/year
More informationMechanical Circulatory Support (MCS): What Every Pharmacist Needs to Know!
Mechanical Circulatory Support (MCS): What Every Pharmacist Needs to Know! Matthew A. Wanat, PharmD, BCPS, BCCCP, FCCM Clinical Assistant Professor University of Houston College of Pharmacy Clinical Pharmacy
More informationDo we really need an Artificial Heart? No!! John V. Conte, MD, Professor of Surgery Johns Hopkins University School of Medicine
Do we really need an Artificial Heart? No!! John V. Conte, MD, Professor of Surgery Johns Hopkins University School of Medicine Division of Cardiac Surgery The Johns Hopkins Medical Institutions Conflict
More informationImplantable Ventricular Assist Devices and Total Artificial Hearts. Policy Specific Section: June 13, 1997 March 29, 2013
Medical Policy Implantable Ventricular Assist Devices and Total Artificial Hearts Type: Medical Necessity and Investigational / Experimental Policy Specific Section: Surgery Original Policy Date: Effective
More informationPercutaneous Mechanical Circulatory Support Devices
Percutaneous Mechanical Circulatory Support Devices Daniel Vazquez RN, RCIS Miami Cardiac & Vascular Institute FINANCIAL DISCLOSURES none CASE STUDY CASE STUDY 52 year old gentlemen Complaining of dyspnea
More informationPediatric Mechanical Circulatory Support (MCS)
Pediatric Mechanical Circulatory Support (MCS) Ivan Wilmot, MD Heart Failure, Transplant, MCS Assistant Professor The Heart Institute Cincinnati Children s Hospital Medical Center The University of Cincinnati
More informationVentricular Assisting Devices in the Cathlab. Unrestricted
Ventricular Assisting Devices in the Cathlab Unrestricted What is a VAD? A single system device that is surgically attached to the left ventricle of the heart and to the aorta for left ventricular support
More informationFurther devices to treat heart failure
Postgraduate Course Heart Failure Further devices to treat heart failure Pr. Matthias Kirsch Department of Cardiac Surgery Centre Hospitalo-Universitaire Vaudois Université de Lausanne e-mail: matthias.kirsch@chuv.ch
More informationMEDICAL POLICY SUBJECT: VENTRICULAR ASSIST DEVICES
MEDICAL POLICY PAGE: 1 OF: 7 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical policy criteria are not applied.
More informationStatus of Implantable VADs
Status of Implantable VADs John V. Conte, MD, Professor of Surgery Johns Hopkins University School of Medicine Division of Cardiac Surgery The Johns Hopkins Medical Institutions Conflict of Interest Statement
More informationRationale for Prophylactic Support During Percutaneous Coronary Intervention
Rationale for Prophylactic Support During Percutaneous Coronary Intervention Navin K. Kapur, MD, FACC, FSCAI Assistant Director, Interventional Cardiology Director, Interventional Research Laboratories
More informationNew ventricular assist devices. FW Mohr Clinical seminar: Devices for severe heart failure ESC congress Stockholm 2010
New ventricular assist devices FW Mohr Clinical seminar: Devices for severe heart failure ESC congress Stockholm 2010 The real world of CHF Prevalence 1-3% in europe, in the age of 70-80 years up to 10-20%
More informationECMO as a Bridge to Heart Transplant in the Era of LVAD s.
Christian Bermudez MD. Associate Professor Director Thoracic Transplantation Division Cardiac Surgery Department of Surgery University of Pennsylvania ECMO as a Bridge to Heart Transplant in the Era of
More informationPlanned, Short-Term RVAD During Durable LVAD Implant: Indications and Management
Planned, Short-Term RVAD During Durable LVAD Implant: Indications and Management Yoshifumi Naka, MD, PhD Columbia University Medical Center New York, NY Disclosure Abbott/St. Jude Med./Thoratec Consultant
More informationImplantable Ventricular Assist Devices and Total Artificial Hearts
Implantable Ventricular Assist Devices and Total Artificial Hearts Policy Number: Original Effective Date: MM.06.017 05/21/1999 Line(s) of Business: Current Effective Date: PPO; HMO; QUEST Integration
More informationRay Matthews MD Professor of Clinical Medicine Chief of Cardiology University of Southern California
High Risk PCI Making Possible the Impossible Ray Matthews MD Professor of Clinical Medicine Chief of Cardiology University of Southern California Disclosures Abiomed Research Support Consulting Agreement
More informationAcute heart failure: ECMO Cardiology & Vascular Medicine 2012
Acute heart failure: ECMO Cardiology & Vascular Medicine 2012 Lucia Jewbali cardiologist-intensivist 14 beds/8 ICU beds Acute coronary syndromes Heart failure/ Cardiogenic shock Post cardiotomy Heart
More informationLVAD Complications, Recovery
LVAD Complications, Recovery Abbas Ardehali, M.D., F.A.C.S. Professor of Surgery and Medicine, Division of Cardiac Surgery William E. Connor Chair in Cardiothoracic Transplantation Director, UCLA Heart,
More informationImplantable Ventricular Assist Devices and Total Artificial Hearts
Implantable Ventricular Assist Devices and Total Artificial Hearts Policy Number: Original Effective Date: MM.06.017 05/21/1999 Line(s) of Business: Current Effective Date: PPO; HMO; QUEST Integration
More informationCandidate Selection for Long Term VAD
6th Saudi Heart Failure Symposium Riyadh - December 9, 2017 Candidate Selection for Long Term VAD AMMAR CHAUDHARY, MBCHB, FRCPC Consultant Cardiologist Advanced Heart Failure Department of Cardiology King
More informationLessons learned from ENDURANCE, ROADMAP, MedaMACS, and how to go forward?
Lessons learned from ENDURANCE, ROADMAP, MedaMACS, and how to go forward? Mark S. Slaughter, MD Professor and Chair Department of Cardiovascular and Thoracic Surgery University of Louisville What could
More informationAdvances in Advanced Heart Failure Therapies. Disclosures. Management Algorithm for Patients in Cardiogenic Shock
Advances in Advanced Heart Failure Therapies 9 th Annual Dartmouth Conference on Advances in Heart Failure Therapies Dartmouth-Hitchcock Medical Center May 20, 2013 Joseph G. Rogers, M.D. Associate Professor
More informationWhich mechanical assistance for cardiogenic shock?
Which mechanical assistance for cardiogenic shock? Alain Combes, MD, PhD, Hôpital Pitié-Salpêtrière, AP-HP Inserm UMRS 1166, ican, Institute of Cardiometabolism and Nutrition Pierre et Marie Curie Sorbonne
More informationJennifer A. Brown The Cleveland Clinic School of Perfusion Cleveland, Ohio
Biventricular Heart Failure Advanced Treatment Options at The Cleveland Clinic Jennifer A. Brown The Cleveland Clinic School of Perfusion Cleveland, Ohio I have no disclosures. Examine respiratory and
More informationWhat are the indications for Tricuspid valve repair during LVAD Implant RANJIT JOHN, MD UNIVERSITY OF MINNESOTA
What are the indications for Tricuspid valve repair during LVAD Implant RANJIT JOHN, MD UNIVERSITY OF MINNESOTA Contraindications for LVAD Lack of social support system Nonreversible end organ failure
More informationTotal Artificial Hearts and Implantable Ventricular Assist Devices
Total Artificial Hearts and Implantable Ventricular Assist Devices Policy Number: 7.03.11 Last Review: 12/2013 Origination: 12/2001 Next Review: 12/2014 Policy Blue Cross and Blue Shield of Kansas City
More informationIntraaortic Balloon Counterpulsation- Supportive Data for a Role in Cardiogenic Shock ( Be Still My Friend )
Intraaortic Balloon Counterpulsation- Supportive Data for a Role in Cardiogenic Shock ( Be Still My Friend ) Stephen G. Ellis, MD Section Head, Interventional Cardiology Professor of Medicine Cleveland
More informationSeventh INTERMACS annual report: 15,000 patients and counting
http://www.jhltonline.org INTERMACS ANNUAL REPORT Seventh INTERMACS annual report: 15,000 patients and counting James K. Kirklin, MD, a David C. Naftel, PhD, a Francis D. Pagani, MD, PhD, b Robert L. Kormos,
More informationRisk Factors for Adverse Outcome after HeartMate II Jennifer Cowger, MD, MS St. Vincent Heart Center of Indiana
Risk Factors for Adverse Outcome after HeartMate II Jennifer Cowger, MD, MS St. Vincent Heart Center of Indiana Advanced Heart Failure, Transplant, & Mechanical Circulatory Support Relevant Financial Relationship
More informationCASE PRESENTATION Ravi Dhanisetty, M.D. SUNY Downstate 23 July 2009 CASE PRESENTATION xx yr old female with chest pain for 3 days. Initially taken to outside hospital 3 days history of chest pain, shortness
More informationTranslating Device and Mechanical Support Guidelines to ACHD Research. Timothy M. Maul, CCP, PhD Perfusionist Sr. Research Scientist
Translating Device and Mechanical Support Guidelines to ACHD Research Timothy M. Maul, CCP, PhD Perfusionist Sr. Research Scientist Disclosures No financial disclosures May discuss off-label or investigational
More informationHow to mend a broken heart: transplantation or LVAD?
SCDU DI CARDIOCHIRURGIA Università degli Studi di Torino Ospedale S. Giovanni Battista Direttore: Prof. Mauro Rinaldi How to mend a broken heart: transplantation or LVAD? Massimo Boffini Mauro Rinaldi
More informationTotal Artificial Hearts and Implantable Ventricular Assist Devices
Total Artificial Hearts and Implantable Ventricular Assist Devices Policy Number: 7.03.11 Last Review: 12/2018 Origination: 12/2001 Next Review: 12/2019 Policy Blue Cross and Blue Shield of Kansas City
More informationImplantable Ventricular Assist Devices and Total Artificial Hearts
Implantable Ventricular Assist Devices and Total Artificial Hearts Policy Number: Original Effective Date: MM.06.017 05/21/1999 Line(s) of Business: Current Effective Date: PPO; HMO; QUEST Integration
More informationDescription. Section: Surgery Effective Date: April 15, Subsection: Transplant Original Policy Date: September 13, 2012 Subject:
Last Review Status/Date: March 2016 Page: 1 of 30 Description Mechanical devices to assist or replace a failing heart have been developed over many decades of research. A ventricular assist device (VAD)
More informationName of Policy: Ventricular Assist Devices and Total Artificial Hearts
Name of Policy: Ventricular Assist Devices and Total Artificial Hearts Policy #: 033 Latest Review Date: February 2014 Category: Surgery Policy Grade: A Background/Definitions: As a general rule, benefits
More informationCardiogenic Shock and Initiatives to Reduce Mortality
Cardiogenic Shock and Initiatives to Reduce Mortality Tanveer Rab, MD, FACC William O Neill, MD, FACC Perwaiz Meraj, MD, FACC Alex Truesdell, MD, FACC The Golden Hours? 50% dead within 10 hours Overall
More informationVAD come Destination therapy nell adulto con Scompenso Cardiaco
VAD come Destination therapy nell adulto con Scompenso Cardiaco Francesco Santini Division of Cardiac Surgery, IRCCS San Martino IST University of Genova Medical School, Italy Heart Transplantation is
More informationOutpatient Treatment of MCS Patient. F. Bennett Pearce, MD Professor of Pediatrics Med Director Heart Transplant COA
Outpatient Treatment of MCS Patient F. Bennett Pearce, MD Professor of Pediatrics Med Director Heart Transplant COA Disclosure Statement I DO NOT HAVE ANY RELEVANT FINANCIAL RELATIONSHIPS WITH ANY COMMERCIAL
More informationArtificial Heart Program
Artificial Heart Program Provider Review: General VAD Overview Indications for VAD Bridge to transplant (BTT) historically most common (~80%) allow rehab from severe CHF while awaiting donor Bridge to
More informationTotal Artificial Hearts and Implantable Ventricular Assist Devices
Total Artificial Hearts and Implantable Ventricular Assist Devices Policy Number: 7.03.11 Last Review: 12/2017 Origination: 12/2001 Next Review: 12/2018 Policy Blue Cross and Blue Shield of Kansas City
More informationDescription. Section: Surgery Effective Date: January 15, 2015 Subsection: Transplant Original Policy Date: September 13, 2012 Subject:
Last Review Status/Date: December 2014 Page: 1 of 26 Description Mechanical devices to assist or replace a failing heart have been developed over many decades of research. A ventricular assist device (VAD)
More informationDerivation and Validation of a Novel Right-Sided Heart Failure Model After Implantation of Continuous Flow Left Ventricular Assist Devices: the EUROMACS-RHF Risk Score Osama I.I. Soliman, MD, PhD, FACC,
More informationORIGINAL ARTICLE. Alexander M. Bernhardt a, *, Theo M.M.H. De By b, Hermann Reichenspurner a and Tobias Deuse a. Abstract INTRODUCTION
European Journal of Cardio-Thoracic Surgery 48 (2015) 158 162 doi:10.1093/ejcts/ezu406 Advance Access publication 29 October 2014 ORIGINAL ARTICLE Cite this article as: Bernhardt AM, De By TMMH, Reichenspurner
More informationVentricular Assist Devices (VADs) and Percutaneous Cardiac Support Systems
Medical Coverage Policy Effective Date... 2/15/2018 Next Review Date... 2/15/2019 Coverage Policy Number... 0054 Ventricular Assist Devices (VADs) and Percutaneous Cardiac Support Systems Table of Contents
More informationWhat has INTERMACS Taught Us about Patient Outcomes with Durable MCS? James K. Kirklin, MD
What has INTERMACS Taught Us about Patient Outcomes with Durable MCS? James K. Kirklin, MD Disclosure: I am Director of the Data Coordinating Center for the INTERMACS project and receive support through
More informationCABG for ischemic cardiomyopathy, post myocardial infarction and cardiogenic shock
CABG for ischemic cardiomyopathy, post myocardial infarction and cardiogenic shock Yoshiya Toyoda, MD, PhD William Maul Measey Professor of Surgery Chief, Cardiovascular Surgery Surgical Director, Mechanical
More informationHow do Readmissions Impact Survival among Patients with Continuous-Flow Left Ventricular Assist Devices? Findings from INTERMACS
How do Readmissions Impact Survival among Patients with Continuous-Flow Left Ventricular Assist Devices? Findings from INTERMACS Rey P. Vivo, MD 1 ; Selim R. Krim, MD 2 ; Jerry D. Estep, MD 3 ; Wissam
More informationNumber: Policy *Please see amendment for Pennsylvania Medicaid at the end. Last Review 03/23/2017 Effective: 03/25/2003 Next Review: 07/26/2018
1 of 47 Number: 0654 Policy *Please see amendment for Pennsylvania Medicaid at the end of this CPB. Aetna considers a Food and Drug Administration (FDA) approved ventricular assist device (VAD)* medically
More informationHeart Transplantation is Dead
Heart Transplantation is Dead Alternatives to Transplantation in Heart Failure Sagar Damle, MD University of Colorado Health Sciences Center Grand Rounds September 8, 2008 Outline Why is there a debate?
More informationVENTRICULAR ASSIST DEVICES AND TOTAL ARTIFICIAL HEARTS
VENTRICULAR ASSIST DEVICES AND TOTAL ARTIFICIAL HEARTS Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures,
More informationI have nothing to disclose.
I have nothing to disclose. Right ventricular failure and need for biventricular support Friedrich Wilhelm Mohr, MD, PhD Munich, August 27, 2012 Male; date of birth: 19.07.1984 Out clinic visit 10/ 2004:
More informationInnovative ECMO Configurations in Adults
Innovative ECMO Configurations in Adults Practice at a Single Center with Platinum Level ELSO Award for Excellence in Life Support Monika Tukacs, BSN, RN, CCRN Columbia University Irving Medical Center,
More informationAcute Circulatory Support Should We or Shouldn t We?
Acute Circulatory Support Should We or Shouldn t We? Navin K. Kapur, MD, FACC, FSCAI Assistant Professor, Division of Cardiology Director, Acute Circulatory Support Program Director, Interventional Research
More informationVentricular Assist Devices and Total Artificial Hearts
Medical Policy Manual Surgery, Policy No. 52 Ventricular Assist Devices and Total Artificial Hearts Next Review: December 2018 Last Review: January 2018 Effective: February 1, 2018 IMPORTANT REMINDER Medical
More informationEnd-Stage Heart Failure Care: Advances in Technology and Patient Survival
End-Stage Heart Failure Care: Advances in Technology and Patient Survival Colleen Ciampa, RN, MN, CNS, NP-C St. Vincent Hospital Advanced Heart Failure, Transplant, & Mechanical Circulatory Support Program
More informationCardiogenic Shock Protocol
Cardiogenic Shock Protocol Impella Devices Best Practices in AMI Cardiogenic Shock Identify 1-3 SBP < 90 mmhg or on inotropes /pressors Cold, clammy, tachycardia Lactate elevated > 2 mmoi /L Stabilize
More informationMEDICAL POLICY SUBJECT: VENTRICULAR ASSIST DEVICES. POLICY NUMBER: CATEGORY: Technology Assessment
MEDICAL POLICY SUBJECT: VENTRICULAR ASSIST DEVICES PAGE: 1 OF: 8 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product (including
More information